Taddei, Stefano

Cardiovascular and renal outcomes with empagliflozin in heart failure

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 5,206

Empagliflozin in heart failure with a preserved ejection fraction

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 4,874

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)

Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 3,473

Age-Related Reduction of NO Availability and Oxidative Stress in Humans

Taddei, S., Virdis, A., Ghiadoni, L., Salvetti, G., Bernini, G., Magagna, A., & Salvetti, A. (2001) · Hypertension

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 664

Cigarette Smoking and Hypertension

Virdis, A., Giannarelli, C., Fritsch Neves, M., Taddei, S., & Ghiadoni, L. (2010) · Current Pharmaceutical Design

Cardiovascular Health and Disease PreventionSmoking Behavior and Cessation

Cited by 549

Is oxidative stress a therapeutic target in cardiovascular disease?

Münzel, T., Gori, T., Bruno, R. M., & Taddei, S. (2010) · European Heart Journal

Nitric Oxide and Endothelin EffectsAntioxidant Activity and Oxidative Stress

Cited by 470

Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy

Taddei, S., Caraccio, N., Virdis, A., Dardano, A., Versari, D., Ghiadoni, L., Salvetti, A., Ferrannini, E., & Monzani, F. (2003) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsNitric Oxide and Endothelin Effects

Cited by 431

Endothelium‐dependent contractions in hypertension

Vanhoutte, P. M., Feletou, M., & Taddei, S. (2005) · British Journal of Pharmacology

Nitric Oxide and Endothelin EffectsEicosanoids and Hypertension Pharmacology

Cited by 284

Cyclooxygenase-2 Inhibition Improves Vascular Endothelial Dysfunction in a Rat Model of Endotoxic Shock: Role of Inducible Nitric-Oxide Synthase and Oxidative Stress

Virdis, A., Colucci, R., Fornai, M., Blandizzi, C., Duranti, E., Pinto, S., Bernardini, N., Segnani, C., Antonioli, L., Taddei, S., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics

Nitric Oxide and Endothelin EffectsInflammatory mediators and NSAID effects

Cited by 102

Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study)

Parati, G., Omboni, S., Compare, A., Grossi, E., Callus, E., Venco, A., Destro, M., Villa, G., Palatini, P., Rosei, E. A., et al. (2013) · Trials

Blood Pressure and Hypertension StudiesMedication Adherence and Compliance

Cited by 49

Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures

Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology

Heart Failure Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 16